Valuation: Matinas BioPharma Holdings, Inc.

Market Cap 3.92M 3.43M 3.17M 2.95M 5.57M 371M 5.67M 38M 14.75M 183M 14.73M 14.4M 637M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value 1.28M 1.12M 1.03M 961K 1.81M 121M 1.84M 12.36M 4.8M 59.52M 4.79M 4.69M 207M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.89%
Yield 2024 *
-
Yield 2025 -
1 day-7.83%
1 week-5.86%
1 month-24.44%
3 months+22.40%
6 months+4.44%
Current year+4.44%
1 week 0.61
Extreme 0.61
0.69
1 month 0.6
Extreme 0.6
0.88
Current year 0.48
Extreme 0.48
0.88
1 year 0.48
Extreme 0.48
3.09
3 years 0.47
Extreme 0.4748
44.5
5 years 0.47
Extreme 0.4748
80.5
10 years 0.47
Extreme 0.4748
199.5
Manager TitleAgeSince
Chief Executive Officer 51 2018-03-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 51 2025-03-13
Director/Board Member 52 2025-02-04
Director/Board Member 65 2025-02-12
Date Insider Type Main position Quantity % Market Cap.
25-04-29Free

Director

11,600 0.2280%
25-04-29Free

Director

11,600 0.2280%
25-04-29Free

Chief Executive Officer

70,100 1.3780%
Change 5-day change 1-year change 3-year change Capi.($)
-7.83%-5.86%-31.24%-96.60% 4.25M
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average -0.06%+6.01%+31.94%+89.10% 23.14B
Weighted average by Cap. +0.80%+5.21%+48.48%+114.83%

Financials

2024 2025
Net sales - -
Net income -24.25M -21.23M -19.59M -18.28M -34.44M -2.29B -35.05M -235M -91.25M -1.13B -91.11M -89.08M -3.94B -10.34M -9.05M -8.36M -7.8M -14.69M -978M -14.95M -100M -38.93M -483M -38.87M -38M -1.68B
Net Debt -4.39M -3.84M -3.55M -3.31M -6.23M -415M -6.35M -42.55M -16.52M -205M -16.49M -16.12M -714M -2.64M -2.32M -2.14M -1.99M -3.76M -250M -3.82M -25.64M -9.95M -123M -9.94M -9.72M -430M
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
26-06-30 US$0.6120 -7.83% 39,575
26-06-29 US$0.6640 +3.36% 58,414
26-06-26 US$0.6424 +3.15% 53,459
26-06-25 US$0.6228 -4.18% 94,934
26-06-24 US$0.6500 -0.02% 49,626

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTNB Stock